Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.89 - $7.65 $152,079 - $237,915
-31,100 Reduced 55.64%
24,800 $125,000
Q4 2023

Feb 14, 2024

SELL
$4.98 - $6.77 $70,716 - $96,134
-14,200 Reduced 20.26%
55,900 $334,000
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $365,695 - $431,640
54,500 Added 349.36%
70,100 $496,000
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $20,880 - $26,430
3,000 Added 23.81%
15,600 $109,000
Q1 2023

May 15, 2023

SELL
$7.94 - $11.84 $192,148 - $286,528
-24,200 Reduced 65.76%
12,600 $105,000
Q4 2022

Feb 14, 2023

SELL
$10.5 - $14.2 $176,400 - $238,560
-16,800 Reduced 31.34%
36,800 $422,000
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $578,344 - $793,816
53,600 New
53,600 $675,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.43B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.